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Prognostic Value of Reading-to-Reading Blood Pressure
Variability Over 24 Hours in 8938 Subjects From
11 Populations
Tine W. Hansen, Lutgarde Thijs, Yan Li, Jose´ Boggia, Masahiro Kikuya, Kristina Bjo¨rklund-Bodegård,
Tom Richart, Takayoshi Ohkubo, Jørgen Jeppesen, Christian Torp-Pedersen, Eamon Dolan,
Tatiana Kuznetsova, Katarzyna Stolarz-Skrzypek, Vale´rie Tikhonoff, Sofia Malyutina,
Edoardo Casiglia, Yuri Nikitin, Lars Lind, Edgardo Sandoya, Kalina Kawecka-Jaszcz, Yutaka Imai,
Jiguang Wang, Hans Ibsen, Eoin O’Brien, Jan A. Staessen, for the International Database on
Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators
Abstract—In previous studies, of which several were underpowered, the relation between cardiovascular outcome and blood
pressure (BP) variability was inconsistent. We followed health outcomes in 8938 subjects (mean age: 53.0 years; 46.8%
women) randomly recruited from 11 populations. At baseline, we assessed BP variability from the SD and average real
variability in 24-hour ambulatory BP recordings. We computed standardized hazard ratios (HRs) while stratifying by cohort
and adjusting for 24-hour BP and other risk factors. Over 11.3 years (median), 1242 deaths (487 cardiovascular) occurred, and
1049, 577, 421, and 457 participants experienced a fatal or nonfatal cardiovascular, cardiac, or coronary event or a stroke.
Higher diastolic average real variability in 24-hour ambulatory BP recordings predicted (P0.03) total (HR: 1.14) and
cardiovascular (HR: 1.21) mortality and all types of fatal combined with nonfatal end points (HR:1.07) with the exception
of cardiac and coronary events (HR: 1.02; P0.58). Higher systolic average real variability in 24-hour ambulatory BP
recordings predicted (P0.05) total (HR: 1.11) and cardiovascular (HR: 1.16) mortality and all fatal combined with
nonfatal end points (HR:1.07), with the exception of cardiac and coronary events (HR:1.03; P0.54). SD predicted
only total and cardiovascular mortality. While accounting for the 24-hour BP level, average real variability in 24-hour
ambulatory BP recordings added 1% to the prediction of a cardiovascular event. Sensitivity analyses considering
ethnicity, sex, age, previous cardiovascular disease, antihypertensive treatment, number of BP readings per recording,
or the night:day BP ratio were confirmatory. In conclusion, in a large population cohort, which provided sufficient
statistical power, BP variability assessed from 24-hour ambulatory recordings did not contribute much to risk
stratification over and beyond 24-hour BP. (Hypertension. 2010;55:1049-1057.)
Key Words: blood pressure variability  ambulatory blood pressure  population science
 risk factors  epidemiology
Ambulatory blood pressure monitoring not only providesinformation on the blood pressure level but on the
diurnal changes in blood pressure as well. Blood pressure
variability includes both short-term and circadian compo-
nents, which can be estimated by the SD of the blood pressure
values over a defined period of the day or by the night:day
blood pressure ratio, respectively. We recently reported in
7000 subjects recruited from 6 populations on the prognos-
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tic accuracy of long-term blood pressure variability.1 Both
daytime and nighttime blood pressure consistently predicted
the composite end point of all cardiovascular events. Ad-
justed for the 24-hour blood pressure, the night:day blood
pressure ratio predicted mortality but not fatal combined with
nonfatal events.
Although the aforementioned analyses shed light on the
association between outcome and long-term blood pressure
variability, the predictive value of short-term reading-to-
reading blood pressure variability remains uncertain. Possible
limitations of previous studies were a lack of statistical
power,2–5 selection of specific groups of patients,5–7 catego-
rization of variability by arbitrary cutoff points,2,4,7–9 and sole
reliance on fatal end points.10,11 Moreover, various parame-
ters can capture short-term blood pressure variability over 24
hours, but most studies only considered the SD of systol-
ic4,6,12 or diastolic blood pressure or both.8–10 To address the
prognostic value of short-term blood pressure variability, we
expanded, updated, and analyzed the International Database
on Ambulatory Blood Pressure in Relation to Cardiovascular
Outcome.
Methods
Study Population
Previous publications described the construction of the International
Database on Ambulatory Blood Pressure in Relation to Cardiovas-
cular Outcome.1,13–15 Studies were eligible for inclusion if they
involved a random population sample, if baseline information on
ambulatory blood pressure and cardiovascular risk factors was
available, and if the subsequent follow-up included fatal and nonfatal
outcomes. At the time of writing this report, the International
Database on Ambulatory Blood Pressure in Relation to Cardiovas-
cular Outcome included prospective studies from 11 centers (11 785
subjects). All studies received ethical approval and have been
reported in peer-reviewed publications. In line with previous re-
ports,1,13–15 we excluded 252 participants because they were 18
years of age and 1892 participants because they had 10 daytime or
5 nighttime blood pressure readings. For the analyses of the
variability, we additionally disregarded 703 subjects because they
had missing readings during 3 consecutive hours. The 8938 analyzed
participants were 2018 residents from Copenhagen, Denmark16;
1086 subjects from Noorderkempen, Belgium17; 1069 older men
from Uppsala, Sweden18; 226 subjects from Novosibirsk, the Rus-
sian Federation19,20; 1430 inhabitants from Ohasama, Japan21; 346
villagers from the JingNing county, China22; 1093 subjects from
Montevideo, Uruguay23; 161 subjects from Pilsen, the Czech Repub-
lic20; 900 subjects from Dublin, Ireland24; 303 subjects from Padova,
Italy20; and 306 subjects from Krako´w, Poland.20 All participants
gave informed written consent.
Blood Pressure Measurements
Conventional blood pressure was measured by trained observers with a
mercury sphygmomanometer16–20,22,24; with validated auscultatory21
(USM-700F, UEDA Electronic Works) or oscillometric23 (OMRON
HEM-705CP, Omron Corporation) devices, using the appropriate
cuff size; and with participants in the sitting16,17,19–24 or supine18
position. Conventional blood pressure was the average of 2 consec-
utive readings obtained either at the person’s home17,19,20,22,23 or at
an examination center.16,18,21,24 Hypertension was a conventional
blood pressure of 140 mm Hg systolic or 90 mm Hg diastolic or
the use of antihypertensive drugs.
We programmed portable monitors to obtain ambulatory blood
pressure readings at 30-minute intervals throughout the whole
day21,24 or at intervals ranging from 1516 to 3018 minutes during
daytime and from 3016 to 6018 minutes at night. The devices
implemented an auscultatory algorithm (Accutracker II) in Uppsala18
or an oscillometric technique (SpaceLabs 90202 and 90207, Nippon
Colin, and ABPM-630) in the other cohorts.17–24 While accounting
for the daily pattern of activities of the participants, we defined
daytime as the interval from 10:00 AM to 8:00 PM in Europeans16–20,24
and South Americans23 and from 8:00 AM to 6:00 PM in Asians.21,22
The corresponding nighttime intervals ranged from 12:00 PM to
6:00 AM16 –20,23,24 and from 10:00 PM to 4:00 AM,21,22 respectively. In
dichotomous analyses, we defined systolic and diastolic nondipping
as a night:day blood pressure ratio of 0.90.1
As measures of short-term reading-to-reading blood pressure
variability, we used the SD over 24 hours weighted for the time
interval between consecutive readings (SD24), the average of the
daytime and nighttime SDs weighted for the duration of the daytime
and nighttime interval (SDdn),25 and the average real variability
weighted for the time interval between consecutive readings (average
real variability in 24-hour ambulatory BP recordings; ARV24).4 The
SDdn is the mean of day and night SD values corrected for the
number of hours included in each of these 2 periods (Figure 1A),
according to the following formula25: SDdn[(day SDhours in-
cluded in the daytime)(night SDhours included in the night-
time)]/(hours included in daytimenighttime). This method removes
the influence of the day-night blood pressure difference from the
estimate of blood pressure variability. The ARV24 averages the
absolute differences of consecutive measurements and accounts in
this manner for the order in which the blood pressure measurements
are obtained (Figure 1B). It is calculated by the following formula:
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Figure 1. A, Average of the daytime and nighttime SDdn and (B)
ARV24. Reproduced with permission from References 25 and 4,
respectively. A, Illustrative 24-hour SBP profile. The SD of the
24-hour systolic blood pressure is substantially higher than the
corresponding daytime and nighttime SDs, separately com-
puted, because of the contribution of the pronounced nocturnal
fall in blood pressure. ARV24 averages the absolute differences
between consecutive readings and thereby accounts for the
order of the blood pressure readings. B illustrates that, for dis-
tinct blood pressure signals, SD can be the same, whereas
ARV24 is not.
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ARV
1
w k1
n1
wBPk1BPk
where k ranges from 1 to N1 and w is the time interval between
BPk and BPk1. N is the number of blood pressure readings.4
Other Measurements
We used the questionnaires originally administered in each cohort to
obtain information on each subject’s medical history and smoking
and drinking habits. Body mass index was body weight in kilograms
divided by height in meters squared. We measured serum cholesterol
and blood glucose by automated enzymatic methods. Diabetes
mellitus was the use of antidiabetic drugs, a fasting blood glucose
concentration of 7.0 mmol/L,16–21,23 a random blood glucose
concentration of 11.1 mmol/L,17,21,22 a self-reported diagno-
sis,17,22,23 or diabetes mellitus documented in practice or hospital
records.23
Ascertainment of Events
In each cohort, outcomes were adjudicated against source documents
described in previous publications.13,18,21,22,26–28 The adjudication
process was the same in the Belgium study28 and in all of the other
studies included in the European Project on Genes in Hypertension
(Novosibirsk, Pilsen, Padova, and Krako´w).29 Outcomes were coded
according to the international classification of diseases (ICD), as
tabulated in the online Data Supplement (Table S1), available at
http://hyper.ahajournals.org.
Fatal and nonfatal stroke (ICD8/9 430 to 434 and 436, and ICD10
I60 to I64, I67 and I68) did not include transient ischemic attacks.
Coronary events encompassed death from ischemic heart disease
(ICD8 411 and 412, ICD9 411 and 414, and ICD10 I20, I24 and I25),
sudden death (CD8 427.2 and 795, ICD9 427.5 and 798, and ICD10
I46 and R96), nonfatal myocardial infarction (ICD8/9 410, and
ICD10 I21 and I22), and coronary revascularization. Cardiac events
were composed of coronary end points and fatal and nonfatal heart
failure (ICD8 428, 427.1, 427.2 and 429, ICD9 429, and ICD10 I50
and J81). Hospitalizations for unstable angina were coded as
ischemic heart disease. In the Danish and Swedish cohorts, the diagnosis
of heart failure required admission to the hospital. In the other cohorts,
heart failure was either a clinical diagnosis or the diagnosis on the
death certificate, but in all cases it was validated against hospital files
or the records held by family doctors. The composite cardiovascular
end point included all aforementioned end points plus cardiovascular
mortality (ICD8 390 to 448, ICD9 390.0 to 459.9, and ICD10 I00 to
I79 and R96). In all outcome analyses, we only considered the first
event within each category.
Statistical Methods
For database management and statistical analysis, we used SAS
software, version 9.1.3 (SAS Institute). For comparison of means and
proportions, we applied the large-sample z test and the 2 statistic,
respectively. We used a Pearson correlation coefficient to assess the
correlations among the 3 measures of short-term blood pressure
variability. Statistical significance was an -level of 0.05 on
2-sided tests. After stratification for cohort and sex, we computed
missing values of body mass index (n916) and serum cholesterol
(n598) from the regression slope on age. In subjects with unknown
smoking status (n38) or drinking habits (n435 among Swedish
men and n316 among the other cohorts), we set the design variable
to the cohort- and sex-specific mean of the codes (0 and 1).
We used Cox regression to compute standardized hazard ratios
(HRs). We checked the proportional hazards assumption by the
Kolmogorov-type supremum test, as implemented in the PROC
PHREG procedure of the SAS package and by testing the interaction
terms between follow-up duration and the variable of interest. We
first plotted incidence rates by fifths of the distributions of systolic
and diastolic blood pressure variability, while standardizing by the
direct method for cohort, sex, and age (40, 40 to 60, and 60
years). We computed HRs while stratifying for cohort and adjusting
for sex and baseline characteristics, including age (used as a
continuous variable), 24-hour heart rate, body mass index, smoking
(0 and 1) and drinking (0 and 1), serum cholesterol, history of
cardiovascular disease (0 and 1), diabetes mellitus (0 and 1), and
treatment with antihypertensive drugs (0 and 1). In fully adjusted
models, we additionally adjusted for the 24-hour systolic or diastolic
blood pressure. We tested heterogeneity in the HRs across subgroups
by introducing the appropriate interaction term in the Cox model.
Finally, we applied the generalized R2 statistic to assess the risks
explained in Cox regression30 by consecutively entering the 24-hour
blood pressure and ARV24 as predictor variables into the models for
the composite cardiovascular end point.
Results
Baseline Characteristics
The study population consisted of 6069 Europeans (67.9%),
1093 Asians (12.2%), and 1176 South Americans (19.9%).
The 8938 participants included 4785 women (46.8%) and
3664 patients with hypertension (41.0%), of whom 1749
(47.7%) were taking blood pressure–lowering drugs. Mean
(SD) age was 53.015.8 years. At enrollment, 2558 par-
ticipants (28.7%) were current smokers, and 4351 (53.1%)
reported intake of alcohol.
Table 1 shows the baseline characteristics by quartiles of
diastolic ARV24. Across quartiles, all characteristics were
significantly different (P0.05). Participants with a higher
blood pressure variability were older, had higher blood
pressure, were more likely to be male, and were more likely
to have diabetes mellitus (Table 1). The ARV24, SD24, and
SDdn were highly correlated with one another; the correlation
coefficients ranged from 0.75 to 0.81 (P0.001) for systolic
blood pressure and from 0.71 to 0.79 (P0.001) for diastolic
blood pressure.
Incidence of Events
In the overall study population, median follow-up was 11.3
years (fifth to 95th percentile interval: 2.5 to 17.6 years).
Across cohorts, median follow-up ranged from 2.5 years
(fifth to 95th percentile interval: 2.3 to 2.6) in JingNing to
17.6 years (fifth to 95th percentile interval: 16.4 to 18.2
years) in Dublin. During 96 041 person-years of follow-up,
1242 participants died (12.9 per 1000 person-years), and
1049 experienced a fatal or nonfatal cardiovascular compli-
cation (11.3 per 1000 person-years). Mortality included 487
cardiovascular and 713 noncardiovascular deaths and 42
deaths from unknown causes (Table 2). Considering cause-
specific first cardiovascular events, the incidence of fatal and
nonfatal stroke amounted to 138 and 371, respectively.
Cardiac events consisted of 172 fatal and 405 nonfatal events,
including 72 fatal and 204 nonfatal cases of acute myocardial
infarction, 50 deaths from ischemic heart diseases, 13 sudden
deaths, 37 fatal and 151 nonfatal cases of heart failure, and 50
cases of surgical or percutaneous coronary revascularization.
For comparison, cohort-specific mortality data and country-
specific mortality statistics published by the World Health
Organization are presented in Table S2.
Risk Associated With Blood Pressure Variability
Figure 2 shows the cohort-, sex-, and age-standardized rates
of mortality and fatal combined with nonfatal outcomes
across quintiles of systolic and diastolic ARV24. The
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multivariable-adjusted and standardized HRs associated with
systolic and diastolic blood pressure variability for mortality
and for all fatal combined with nonfatal cardiovascular events
appear in Table 2.
Mortality
In adjusted models not including the 24-hour blood pressure
level, systolic blood pressure variability predicted both total
and cardiovascular mortality (P0.04), with the exception of
SD24 in relation to total mortality (P0.17). We obtained
similar results after additional adjustment for the 24-hour
systolic blood pressure, with the exception of SD24 and SDdn,
which no longer predicted cardiovascular mortality
(P0.71). Diastolic blood pressure variability predicted total
and cardiovascular mortality both in adjusted and fully
adjusted models (P0.002; Table 2). Blood pressure vari-
ability did not predict noncardiovascular mortality
(0.14P0.75).
Fatal and Nonfatal Cardiovascular Events
In adjusted analyses not including the 24-hour blood pressure
level, systolic blood pressure variability predicted all of the
fatal combined with nonfatal outcomes (P0.03) with the
exception of coronary events (P0.07). However, in fully
adjusted analyses, systolic blood pressure variability lost its
predictive value with the exception of ARV24 in relation to all
cardiovascular events combined and stroke (Table 2).
Diastolic blood pressure variability was predictive of all of
the combined end points (P0.03), with the exception of
coronary events (P0.15). In fully adjusted models, diastolic
blood pressure variability only predicted all cardiovascular
events combined (ARV24 and SDdn) and fatal plus nonfatal
stroke (ARV24). Figure 3 shows the absolute risk of a
combined cardiovascular event in relation to the ARV24 at
different levels of systolic and diastolic 24-hour blood pres-
sure (Figure 3A and 3B) and in relation to 24-hour blood
pressure at different levels of the systolic and diastolic ARV24
(Figure 3C and 3D). The analyses were standardized to the
distributions (mean or ratio) of cohort, sex, age, 24-hour heart
rate, body mass index, smoking and drinking, serum choles-
terol, history of cardiovascular disease, diabetes mellitus, and
treatment with antihypertensive drugs. Absolute risk in-
creased with both the 24-hour blood pressure (P0.001) and
ARV24 (P0.04). However, with the 24-hour blood pressure
in the model, ARV24 added only 0.1% to the explained risk of
a composite cardiovascular event (Table 3).
Sensitivity Analyses
In sensitivity analyses, we considered total mortality and all
cardiovascular events combined in relation to diastolic and
systolic ARV24 (Tables S3 and S4). We stratified the study
population according to sex; median age (60 years); antihy-
pertensive treatment; the presence or absence of hyperten-
sion; European, Asian, or South American origin; numbers of
Table 1. Baseline Characteristics of Participants
Characteristic
Quartiles of Diastolic Average Real Variability, Limits, mm Hg
6.9 6.9 to8.1 8.1 to9.6 9.6
Subjects with characteristic
All subjects in quartile, n 2235 2235 2234 2234
European, n (%) 1428 (63.9) 1586 (71.0) 1575 (70.5) 1480 (66.3)
Asian, n (%) 666 (29.8) 437 (19.6) 347 (15.5) 326 (14.6)
South American, n (%) 141 (6.3) 212 (9.5) 312 (14.0) 428 (19.2)
Women, n (%) 1225 (54.8) 1072 (48.0) 983 (44.0) 905 (40.5)
Antihypertensive treatment, n (%) 331 (14.8) 373 (16.7) 456 (20.4) 589 (26.4)
Smokers, n (%) 644 (28.9) 675 (30.3) 661 (29.7) 578 (26.1)
Using alcohol, n (%) 1065 (51.2) 1182 (56.6) 1181 (57.0) 923 (47.5)
Diabetes mellitus, n (%) 124 (5.6) 136 (6.1) 132 (5.9) 192 (8.6)
Cardiovascular disorder, n (%) 140 (6.3) 135 (6.0) 185 (8.3) 244 (10.9)
MeanSD of characteristic
Age, y 50.114.8 51.415.2 53.416.1 57.016.2
Body mass index, kg/m2 24.23.6 25.14.1 25.94.0 26.44.4
Ambulatory measurements
24-hour systolic, mm Hg 118.512.1 122.112.7 125.013.8 128.814.9
24-hour diastolic, mm Hg 71.88.0 72.78.1 74.08.1 75.98.6
Daytime systolic, mm Hg 124.613.1 128.513.6 131.915.2 135.015.7
Daytime diastolic, mm Hg 76.78.6 77.88.8 79.38.9 81.09.6
Nighttime systolic, mm Hg 107.912.6 110.613.7 112.814.5 116.916.9
Nighttime diastolic, mm Hg 63.18.6 63.68.8 64.58.9 66.39.8
24-hour heart rate, bpm 71.18.6 71.79.0 72.19.0 73.19.5
Serum cholesterol, mmol/L 5.41.1 5.61.2 5.81.2 5.71.2
Trends across quartiles were significant (P0.05) for all characteristics.
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blood pressure readings in individual blood pressure record-
ings; and dipping status dichotomized by a night:day blood
pressure ratio of 0.9. HRs were not statistically different
across strata (0.07P0.93) with 2 exceptions. First, the HR
for diastolic ARV24 in relation to total mortality was higher in
treated than untreated subjects (1.20 versus 1.04; P0.02).
Second, the HR for diastolic ARV24 in relation to all
cardiovascular events was higher in Asians than in Europeans
(1.36 versus 1.04; P0.009) but similar in Europeans and
South Americans (P0.20). The predictive value of systolic
ARV24 was similar across all strata (Table S4;
0.07P0.88).
Analyses on the basis of daytime and nighttime ARV were
confirmative but did not attain the significance levels of
ARV24 because of the fewer readings included in the daytime
and nighttime ARV (data not shown). For SD24 and SDdn,
none of the interaction terms with the strata shown in Tables
S3 and S4 reached significance (0.08P0.97).
Discussion
Our current meta-analysis of individual data included 8000
people randomly recruited from 11 populations and covered,
on average, 11 years of follow-up, during which 1242 people
died and 1049 experienced a major cardiovascular complica-
tion. The key finding was that, while accounting for the
24-hour blood pressure level and other covariables, blood
pressure variability was a significant and independent predic-
tor of mortality and of cardiovascular and stroke events.
However, the proportion of the risk explained by the vari-
ability index is low.
For most outcomes, ARV24 was a better predictor than
SD24 and SDdn, probably because, as illustrated in Figure 1,
subjects with different blood pressure profiles might have
similar SDs but different ARV24s. Thus, ARV24 might be a
more specific measure of blood pressure variability than SD.
Several prospective studies in populations4,10–12,31 and
hypertensive patients2,3,5–9 searched for association between
cardiovascular outcomes and blood pressure variability but
reported inconsistent results. This might be because of
insufficient sample size, too few events, varying definitions
of the outcomes of interest, or the use of different indices of
blood pressure variability. To assess blood pressure variabil-
ity, most studies used ambulatory blood pressure monitoring
with intermittent readings at intervals ranging from 158 to 305
minutes throughout 24 hours. In the Northwick Park Study,3
the investigators performed continuous intra-arterial record-
ings but did not fully exploit the potential of this recording
technique. Instead of analyzing variability in the frequency
Table 2. Multivariable-Adjusted Standardized Hazard Ratios Relating Outcome to Blood Pressure Variability
Outcome (No. of Events)
Systolic Blood Pressure Diastolic Blood Pressure
SD24 SDdn ARV24 SD24 SDdn ARV24
SD, mm Hg 15.6 12.2 11.2 11.8 9.1 8.5
Mortality
Total (n1242)
Adjusted 1.05 (0.98 to 1.13) 1.13 (1.06 to 1.21)§ 1.14 (1.06 to 1.22)§ 1.11 (1.04 to 1.19)§ 1.17 (1.09 to 1.24)§ 1.12 (1.05 to 1.19)§
Fully adjusted* 1.00 (0.94 to 1.07) 1.08 (1.01 to 1.15)† 1.11 (1.04 to 1.18)§ 1.09 (1.03 to 1.16)‡ 1.16 (1.09 to 1.23)§ 1.13 (1.07 to 1.19)§
Cardiovascular (n487)
Adjusted 1.11 (1.00 to 1.24)† 1.13 (1.02 to 1.26)† 1.23 (1.11 to 1.36)§ 1.21 (1.10 to 1.34)§ 1.24 (1.13 to 1.36)§ 1.27 (1.17 to 1.38)§
Fully adjusted* 1.03 (0.93 to 1.13) 1.05 (0.95 to 1.17) 1.17 (1.07 to 1.28)† 1.15 (1.05 to 1.26)‡ 1.18 (1.08 to 1.29)§ 1.21 (1.12 to 1.31)§
Fatal and Nonfatal Events
Cardiovascular (n1049)
Adjusted 1.13 (1.06 to 1.22)§ 1.15 (1.07 to 1.24)§ 1.19 (1.11 to 1.27)§ 1.15 (1.07 to 1.23)§ 1.16 (1.09 to 1.24)§ 1.16 (1.09 to 1.23)§
Fully adjusted* 1.02 (0.96 to 1.09) 1.04 (0.97 to 1.11) 1.07 (1.00 to 1.14)† 1.05 (0.99 to 1.12) 1.07 (1.01 to 1.14)† 1.07 (1.01 to 1.13)†
Cardiac (n577)
Adjusted 1.13 (1.02 to 1.24)† 1.11 (1.01 to 1.23)† 1.11 (1.00 to 1.22)† 1.10 (1.00 to 1.20)† 1.11 (1.02 to 1.21)§ 1.10 (1.01 to 1.20)§
Fully adjusted* 1.03 (0.94 to 1.12) 1.01 (0.92 to 1.11) 1.03 (0.94 to 1.13) 1.02 (0.94 to 1.11) 1.03 (0.95 to 1.12) 1.02 (0.94 to 1.11)
Coronary (n421)
Adjusted 1.11 (0.99 to 1.24) 1.09 (0.97 to 1.22) 1.06 (0.94 to 1.19) 1.07 (0.96 to 1.19) 1.08 (0.97 to 1.19) 1.07 (0.97 to 1.19)
Fully adjusted* 1.07 (0.96 to 1.18) 1.04 (0.93 to 1.16) 1.03 (0.93 to 1.14) 1.02 (0.93 to 1.13) 1.02 (0.92 to 1.12) 1.02 (0.92 to 1.12)
Stroke (n457)
Adjusted 1.13 (1.01 to 1.26)† 1.16 (1.04 to 1.30)† 1.25 (1.13 to 1.39)§ 1.22 (1.13 to 1.35)§ 1.22 (1.10 to 1.35)§ 1.26 (1.14 to 1.38)§
Fully adjusted* 0.98 (0.88 to 1.09) 1.03 (0.92 to 1.14) 1.10 (1.00 to 1.21)† 1.08 (0.99 to 1.19) 1.09 (0.99 to 1.20) 1.14 (1.05 to 1.23)†
Values are standardized hazard ratios (HRs), which express the risk per SD increase in the predictor variables. All HRs (95% confidence interval) were computed
by Cox regression stratified for cohort and adjusted for sex, age, 24-hour heart rate, body mass index, smoking and drinking, serum cholesterol, history of
cardiovascular disease, diabetes mellitus, and treatment with antihypertensive drugs.
*Data were additionally adjusted for the corresponding 24-hour blood pressure level.
†P0.05 HR significance.
‡P0.01 HR significance.
§P0.001 HR significance.
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domain, they computed hourly means of blood pressure and
the within-subject SD of the hourly means as a measure of
each participant’s blood pressure variability. In the Ohasama
Study, investigators used the self-measured blood pressure31
in addition to ambulatory blood pressure monitoring.10 In all
but 2 studies,4,7 the researchers used the SD of daytime,
nighttime, or 24-hour blood pressure as an index of variabil-
ity. Four studies5,8–10 deliberately did not report on the
predictive value of the variability in the 24-hour blood
pressure, because the diurnal blood pressure profile also
includes long-term variability, which is captured by the
night:day blood pressure ratio. To address this potential
concern, we computed SDdn and ARV24 as measures of
variability. Only 2 other prospective studies, one in a small
general Venezuelan population (312 subjects with 31 com-
posite cardiovascular end points),4 and one in a hypertensive
population,7 implemented ARV24. Bilo et al25 were the first to
propose SDdn, but to our knowledge there is no prospective
study that has used this index of variability.
Diastolic blood pressure variability tended to be a stronger
predictor of outcome than systolic blood pressure variability.
We can only speculate about the mechanisms underlying this
finding, but arterial stiffness might be involved. In normal
conditions, systolic and diastolic blood pressures change in
parallel in response to physiological stimuli, such as excise or
arousal. However, in subjects with stiff arteries, when systolic
blood pressure increases, often diastolic blood pressure in-
creases less or even falls,32,33 giving rise to larger variability.
On the other hand, a chance finding cannot be excluded.
From a clinical point of view, our current findings suggest
that, although statistically significant, the clinical applicabil-
ity of blood pressure variability for risk stratification might be
limited. First, antihypertensive drug treatment is bound to
influence blood pressure variability. Second, the reproduc-
ibility of blood pressure variability is poor. In 97 normoten-
sive subjects,34 the relative repeatability coefficient of the SD
of the 24-hour blood pressure in individual recordings,
expressed as a percentage of the fifth to 95th percentile
interval in all recordings, was 13% systolic and 16% diastolic,
whereas for the 24-hour blood pressure these coefficients
were 4% and 5%, respectively, lower values, indicating better
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Figure 2. Incidence of mortality (A and C) and car-
diovascular events (B and D) by fifths of the distri-
butions of the systolic (A and B) and diastolic (C
and D) average real variability in 8938 participants.
Incidence rates were standardized for cohort, sex,
and age by the direct method. The number of
events contributing to the rates is presented. CV
and NCV indicate cardiovascular and noncardio-
vascular, respectively.
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reproducibility.34 Finally, the added value in terms of abso-
lute risk was modest in our population. For example, in
adjusted analyses (Figure 3), the increase in the 10-year
absolute risk of a composite cardiovascular event associated
with an increase from the median to the 75th percentile was
0.21% for systolic ARV24 (1.5 mm Hg) and 1.23% for the
24-hour systolic blood pressure (9.8 mm Hg). The corre-
sponding estimates for diastolic ARV24 and for 24-hour
diastolic blood pressure were 0.16% (2.3 mm Hg) and 1.05%
(5.8 mm Hg), respectively.
Notwithstanding the statistical power and the consideration
of fatal and nonfatal events, our study has potential limita-
tions. First, the International Database on Ambulatory Blood
Pressure in Relation to Cardiovascular Outcome is currently
composed of 11 population-based cohorts from 3 continents,
but our results might not yet be generally applicable, in
particular to Africans of black ancestry or African Americans.
Second, we and most other investigators applied intermittent
techniques of ambulatory blood pressure monitoring, which
compared with continuous blood pressure recording, is a less
precise technique to capture short-term blood pressure vari-
ability. However, intra-arterial recordings or continuous re-
cordings of the arterial signal at the finger are difficult, if not
impossible, to implement in large epidemiological studies.
Third, in the current meta-analysis of individual data, blood
pressure variability turned out to provide independent risk
information, and this finding was consistent in stratified
sensitivity analyses. However, even in large cohort studies
with numerous events, the power to detect heterogeneity
across strata is generally low. For example, considering a
2-sided -level of 0.05, we had only 46% power to detect a
0.24 difference between normotensive and hypertensive sub-
jects in the log-transformed HR of all cardiovascular events.
Perspectives
In line with several6–8,10,11 but not all9 previous studies, our
current report established that short-term reading-to-reading
blood pressure variability is an independent risk factor, but
moreover it also highlighted that the level of the 24-hour
blood pressure remains the primary blood pressure–related
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Figure 3. Ten-year absolute risk of combined car-
diovascular events in relation to 24-hour blood
pressure (A and B) at different levels of systolic
and diastolic average real variability over 24 hours
(ARV24) and in relation to ARV24 (C and D) at dif-
ferent levels of 24-hour systolic and diastolic
blood pressure. The analyses were standardized to
the distributions (mean or ratio) of cohort, sex,
age, 24-hour heart rate, body mass index, smok-
ing and drinking, serum cholesterol, history of car-
diovascular disease, diabetes mellitus, and treat-
ment with antihypertensive drugs. In panels A and
B, the risk functions span the 5th to 95th percen-
tile interval of the 24-hour blood pressure and cor-
respond to the 5th, 25th, 50th, 75th and 95th per-
centiles of ARV. In panels C and D, the risk
functions span the 5th to 95th percentile interval
of ARV and correspond to the 5th, 25th, 50th, 75th
and 95th percentiles of the 24-hour blood pres-
sure. P values are for the independent effect of
ARV (Parv) and 24-hour blood pressure (Pbp). np
and ne indicate the number of participants at risk
and the number of events.
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risk factor to account for in clinical practice. This caveat also
applies to the morning surge in blood pressure, as described
in the companion article. Notwithstanding these limitations,
in the setting of clinical research, studies of blood pressure
variability will continue to generate meaningful information.
For research making use of intermittent techniques of ambu-
latory blood pressure monitoring, our current findings suggest
that both SDdn and ARV24 might be useful measures, but not
the SD computed over the whole day, which also includes the
day-night blood pressure difference.
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Appendix  
IDACO Centers and Investigators:  
Belgium (Noorderkempen): R. Fagard, Y. Jin, T. Kuznetsova, T. Richart, J. A. Staessen, L. Thijs; 
China (JingNing): Y. Li, J. Wang; the Czech Republic (Pilsen): J. Filipovský, J. Seidlerová, M. Tichá; 
Denmark (Copenhagen): T. W. Hansen, H. Ibsen, J. Jeppesen, S. Rasmussen, C Torp-Pedersen; Italy 
(Padova): E. Casiglia, A. Pizzioli, V. Tikhonoff; Ireland (Dublin): E. Dolan, E. O’Brien; Japan 
(Ohasama): K. Asayama, J. Hashimoto, H. Hoshi, Y. Imai, R. Inoue, M. Kikuya, H. Metoki, T. Obara, 
T. Ohkubo, H. Satoh, K. Totsune; Poland (Kraków): A. Adamkiewicz-Piejko, M. Cwynar, J. Gąsowski, 
T. Grodzicki, K. Kawecka-Jaszcz, W. Lubaszewski, A. Olszanecka, K. Stolarz, B. Wizner, W. 
Wojciechowska, J. Zyczkowska; the Russian Federation (Novosibirsk): T. Kuznetsova, S. Malyutina, 
Y. Nikitin, E. Pello, G. Simonova, M. Voevoda; Sweden (Uppsala): B. Andrén, L. Berglund, K. 
Björklund-Bodegård, L. Lind, B. Zethelius; Uruguay (Montevideo): M. Bianchi, V. Moreira, E. Sandoya, 
C. Schettini, E. Schwedt, H. Senra. 
Data Base Management and Coordination:   
T. W. Hansen, M. Kikuya, Y.Li, T. Richart, J. A. Staessen (Project Coordinator), and L. Thijs 
(Supervisor Database Management) constructed the IDACO database at the Studies Coordinating 
Centre in Leuven, Belgium.   
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Table S1.   International Classification of Diseases (ICD) Codes Applied in each Cohort   
  Cohort  Stroke  Myocardial infarction Angina pectoris  Heart failure  
Copenhagen  
ICD8 430-434  
and 436,  
ICD10 I60-I64  
ICD8 410,  
ICD10 I21-I22  
ICD8 411-414,  
ICD10 I20 and I23-I25  
ICD8 427.0, 427.1, 
428.0, 429.0, 519.1 
and 782.4,  
ICD10 I50 and J81  
Noorderkempen  ICD8 430-434,  436 and 438  ICD8 410   ICD8 413  
ICD8 427.0, 427.1, 
428.0, 429.0, 519.1 
and 782.4  
Uppsala  
ICD9 430-434  
and 436,  
ICD10 I60-I64  
ICD9 410,  
ICD10 I21 
ICD9 413 and 411.1, 
ICD10 I20  ICD9 429, ICD10 I50 
Dublin  ICD9 430-434   and 436  ICD9 410 and 412  
ICD9 413, 411.1  
and 414  ICD9 428  
Novosibirsk  ICD9 430-434  and 436  ICD9 410 and 412  ICD9 413 and 411.1 ICD9 428  
Pilsen  ICD9 430-434  and 436  ICD9 410 and 412  ICD9 413 and 411.1 ICD9 428  
Padova  ICD9 430-434  and 436  ICD9 410 and 412  ICD9 413 and 411.1 ICD9 428  
Kraków  ICD9 430-438  ICD9 410  ICD9 413  ICD9 428.0-428.4  
Montevideo  ICD10 I60-I64  ICD10 I21-I22  ICD10 I20  ICD10 I50 and J81  
Ohasama  ICD10 I60-I64  ……  ……  ……  
JingNing   ICD9 430-431 and 434  ICD9 410  ICD9 413 
ICD9 428, 427.0  
and 427.1  
…… Not assessed, because of the low incidence in the Ohasama cohort.  
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Table S2.   Cohort-Specific Mortality Data and Country-Specific Mortality Statistics as Published by 
the World Health Organization (WHO).   
 Observed in cohorts  WHO 2002*  
Cohort   All-cause  mortality  
Cardiovascular  
mortality  
Cardiovascular 
mortality  
Noorderkempen (n=2541)  170/2541(7%)  59/170 (35%)  26%  
Copenhagen (n=2311)  393/2311(17%)  136/393 (35%)  26%  
Uppsala (n=1143)  315/1143(28%)  140/315 (44%)  33%  
Dublin (n=981)  36/981 (4%)  19/36 (53%)  30%  
EPOGH† (n=1055)  23/1055 (2%)  6/23 (26%)  37%  
Kraków (n=321)  3/321 (1%)  2/3 (67%)  34%  
Padova (n=310)  4/310 (1%)  0/4 (0%)  28%  
Novosibirsk (n=250)  15/250 (6%)  4/15 (27%)  52%  
Pilsen (n=174)  1/174 (1%)  0/1 (0%)  40%  
Montevideo (n=1859)  124/1859(7%)  46/124 (37%)  25%  
Ohasama (n=1535)  345/1535(22%)  127/345 (37%)  24%  
JingNing (n=360)  14/360 (4%)  6/14 (43%)  26%  
IDACO total (n=8938)§  1242/8938 (14%) 487/1242 (39%)  25.6%‡  
* Country-specific mortality due to ischemic heart disease and cerebrovascular disease, as reported by the World 
Health Organization (http://www.who.int/countries/en/).   
† All 4 centers participating in the European Project on Genes in Hypertension combined.  
‡ Deaths related to ischemic heart disease and cerebrovascular disease in high income countries total in 2004 
http://www.who.int/mediacentre/factsheets/fs310_2008.pdf.  
§ Subjects included in the present analysis.  
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Table S3.  Multivariable-Adjusted Hazard Ratios for Total Mortality and for Fatal and Nonfatal Cardiovascular Events for 
Diastolic Average Real Variability According to Baseline Characteristics  
Strata  At risk (n)  Deaths (n)       Total mortality  Events (n)  Cardiovascular Events  
All participants  8938  1242  1.13 (1.07-1.19)‡  1049  1.07 (1.01-1.13)*  
Women  4186    398  1.19 (1.04-1.36)†     319  1.11 (0.96-1.27)  
Men  4752    844  1.10 (1.02-1.18)*     730  1.10 (1.02-1.19)†   
<60 years  5349    190  1.13 (0.92-1.37)    189  1.04 (0.85-1.24)  
≥60 years  3589  1052  1.11 (1.04-1.19)†     860  1.12 (1.05-1.20)*  
Normotension  5981    605  1.08 (0.97-1.20)    441  1.05 (0.93-1.18)  
Hypertension  2957    637  1.13 (1.04-1.22)†     608  1.13 (1.05-1.22)†   
Nº of readings ≤47  3045    408  1.23 (1.08-1.39)†     330  1.27 (1.12-1.44)†   
Nº of readings 48-71   2891    378  1.13 (1.01-1.26)*    338  1.04 (0.93-1.16)  
Nº of readings >71  3002    456  1.09 (0.96-1.22)    381  1.06 (0.93-1.20)  
Non-dippers  2794    539  1.18 (1.08-1.28)†     428  1.09 (0.99-1.19)  
Dippers  6144    703  1.04 (0.93-1.15)    621  1.12 (1.01-1.24)*  
Untreated  7183    753  1.04 (0.95-1.14)    586  1.04 (0.95-1.14)  
Treated  1749    488  1.20 (1.10-1.32)‡    463  1.16 (1.06-1.27)‡  
Without ß-blocker  1162    344  1.22 (1.05–1.41)*    321  1.18 (1.02-1.36)*  
With ß-blocker    587    144  1.23 (1.06–1.44)*    142  1.08 (0.92-1.27)  
Asian  1776    331  1.21 (1.04-1.41)*    239  1.36 (1.15-1.62)‡  
European  6069    840  1.08 (1.00-1.17)*    724  1.04 (0.96-1.13)  
South American  1093      71  1.29 (1.01-1.63)*      86  1.19 (0.97-1.47)  
Hypertension was a conventional blood pressure of at least 140 mm Hg systolic or 90 mm Hg diastolic or the use of antihypertensive medications.   
Nº of readings refers to the number of blood pressure measurements in a single ambulatory recording. Values are standardized hazard ratios (95% 
confidence interval), which express the risk per SD increase in the predictor variable. All hazard ratios were stratified for cohort and adjusted, as 
appropriate, for sex, age, 24-hour heart rate, body mass index, smoking and drinking, serum cholesterol, history of cardiovascular disease, diabetes 
mellitus, treatment with antihypertensive drugs, and the 24-hour diastolic blood pressure. Significance of the hazard ratios: * P<0.05; † P<0.01; and  
‡ P<0.001. Braces point to heterogeneity between subgroups (P-value for difference between strata given).   
 0.02  
 0.009  
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TABLE S4.  Multivariable-Adjusted Hazard Ratios for Total Mortality and for Fatal and Nonfatal Cardiovascular Events for 
Systolic Average Real Variability According to Baseline Characteristics  
Strata  At risk (n)  Deaths (n)       Total mortality  Events (n)  Cardiovascular Events  
All participants  8938  1242  1.11 (1.04–1.18)‡  1049  1.07 (1.01–1.14)*  
Women  4186    398  1.13 (0.99-1.28)    319  1.04 (0.91-1.20)  
Men  4752    844  1.10 (1.00-1.19)*    730  1.09 (1.00-1.19)*  
<60 years  5349    190  1.15 (0.95-1.38)    189  1.07 (0.89-1.28)  
≥60 years  3589  1052  1.09 (1.01-1.18)*    860  1.09(1.01-1.18)*  
Normotension  5981    605  1.08 (0.97-1.19)    441  1.02 (0.90-1.15)  
Hypertension  2957    637  1.13 (1.02-1.24)†    608  1.13 (1.03-1.24)†  
Nº of readings ≤47  3045    408  1.17 (1.03-1.34)*    330  1.21 (1.05-1.39)†  
Nº of readings 48-71  2891    378  1.09 (0.95-1.25)    338  1.03 (0.90-1.18)  
Nº of readings >71  3002    456  1.09 (0.98-1.22)    381  1.04 (0.92-1.18)  
Non-dippers  2794    539  1.16 (1.04-1.28)†    428  1.05 (0.98-1.16)  
Dippers  6144    703  1.08 (0.97-1.19)    621  1.14 (1.02-1.26)*  
Untreated  7183    753  1.06 (0.96-1.19)    586  1.03 (0.93-1.14)  
Treated  1749    488  1.16 (1.05-1.29)†    463  1.13 (1.02-1.25)*  
Without ß -blocker  1162    344   1.07 (0.93-1.24)    321   1.14 (0.94-1.27)  
With ß-blocker    587    144   1.25 (1.03-1.50)*    142   1.04 (0.88-1.23)  
Asian  1776    331  1.12 (0.96-1.30)    239  1.20 (1.01-1.42)*  
European  6069    840  1.10 (1.01-1.20)*    724  1.04 (0.95-1.14)  
South American  1093      71  1.32 (0.99-1.73)      86  1.10 (0.85-1.42)  
Hypertension was a conventional blood pressure of at least 140 mm Hg systolic or 90 mm Hg diastolic or the use of antihypertensive medications.   
Nº of readings refers to the number of blood pressure measurements in a single ambulatory recording. Values are standardized hazard ratios (95% 
confidence interval), which express the risk per SD increase in the predictor variable. All hazard ratios were stratified for cohort and adjusted, as 
appropriate, for sex, age, 24-hour heart rate, body mass index, smoking and drinking, serum cholesterol, history of cardiovascular disease, diabetes 
mellitus, treatment with antihypertensive drugs, and the 24-hour systolic blood pressure. Significance of the hazard ratios: * P<0.05; † P <0.01; and  
‡ P <0.001. There were no statistically significant differences across the strata according to baseline characteristics (P≥0.07).   
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